Thursday 6th, 13th and 20th July
All webinars run at 3pm BST / 4pm CEST / 10am EDT
Genomics is transforming our understanding of cancer. Recent advances in high-throughput sequencing and other omics technologies are now allowing researchers and drug developers to interrogate the cancer genome like never before with seemingly uncapped potential.
The latest, high-resolution, single-cell and spatial technologies are providing a new wealth of information regarding the malignant functioning of the tumour microenvironment. Whilst the latest genomics technologies are proving instrumental in advancing our understanding of cancer heterogeneity, evolution and immuno-oncology supporting the development of new targeted therapies.
This Cancer Genomics webinar series will fill you in on the latest methods being used to investigate the cancer genome.
Registrants for this series will gain a unique insight into how these methods are enhancing our understanding of cancer biology and ultimately triggering new discoveries.
The webinar series outline is below. Please note, that by registering for the first webinar in the series you will automatically gain access to all subsequent webinars.
– – – – –
Webinar 1: The Latest and Greatest Methods to Interrogate the Tumour Microenvironment
Thursday 6th July at 3pm BST / 4pm CEST / 10am EDT
The tumour microenvironment (TME) is a major source of cancer heterogeneity with a significant influence on the development, progression and treatment of cancer. Therefore, probing the TME has become an increasingly popular avenue to explore for identifying new disease pathways, new therapeutic vulnerabilities, and ultimately new drugs.
Join us to learn how the latest methods are being used to map the tumour microenvironment and how this is arming scientists with new therapeutic targets.
- Single Cell Classification of Tumour Microenvironments in Pan-Cancer Settings
- Sagi Abelson, Principal Investigator, Ontario Institute of Cancer Research
- Cherry-Niche : a tool to “de-construct” the Tumour Microenvironment and functionally characterise the tumour niche
- Luigi Ombrato, Lecturer and Group Lead, Barts Cancer Institute, Queen Mary University London
Webinar 2: Tumour Evolution, Heterogeneity and Identifying New Cancer Drivers
Thursday 13th July at 3pm BST / 4pm CEST / 10am EDT
By studying the evolutionary history of tumours, scientists can uncover the genomic driving forces responsible for cancer onset and progression. This allows researchers to discover new personalised therapies, overcome resistance and even forecast the evolution of disease…
This webinar will show you how understanding cancer evolution and the origins of heterogeneity will allow you to identify new cancer drivers.
- Prostate Cancer Evolution and Ethnicity
- David Wedge, Professor and Group Leader, Cancer Genomics and Tumour Evolution Group, The University of Manchester
- Insights into Lung Cancer Evolution and Metastases in TRACERx
- Mariam Jamal-Hanjani, Clinical Associate Professor and Honorary Consultant, UCL
- Molecular Archaeology of Cancer
- Peter Van Loo, Professor and CPRIT Scholar in Cancer Research, MD Anderson Cancer Center
– – – – –
Webinar 3: Genomics and a Bright Future for Precision Cancer Therapy
Thursday 20th July at 3pm BST / 4pm CEST / 10am EDT
Next-generation sequencing has revolutionized the field of oncology. The latest advances in genomic technologies have come with a deeper understanding of the cancer genome which is leading to the development of new targeted therapies, paving the way for a future of precision medicine and better cancer care.
Join us for this webinar to learn how the latest breakthroughs in cancer genomics are supporting the development of novel cancer therapies and how they will advance clinical decision-making in years to come.
- Personalised Treatment for Bowel Cancer Patients: The Impact of Molecular Pathology and Genomics
- Nicholas West, Associate Professor of Pathology and Honorary Consultant, University of Leeds
- Refining liquid biopsy: generating more information from cell-free DNA
- Páidí Creed, Senior Director of Computational Technologies, Biomodal
- Stratifying Therapy for Patients with Molecular High-Risk Myeloma
- Martin Kaiser, Team Leader of the Myeloma Molecular Therapy Group, ICR
– – – – –
Register here:
Speakers
Sagi Abelson, Principal Investigator, Ontario Institute of Cancer Research
Luigi Ombrato, Lecturer and Group Lead, Barts Cancer Institute, Queen Mary University London
David Wedge, Professor and Group Leader, Cancer Genomics and Tumour Evolution Group, The University of Manchester
Mariam Jamal-Hanjani, Clinical Associate Professor and Honorary Consultant, UCL
Peter Van Loo, Professor and CPRIT Scholar in Cancer Research, MD Anderson Cancer Center
Nicholas West, Associate Professor of Pathology and Honorary Consultant, University of Leeds
Martin Kaiser, Team Leader of the Myeloma Molecular Therapy Group, ICR
